Paloma Giangrande

Paloma Giangrande is a seasoned biotechnology leader currently serving as Chief Technology Officer at Eleven Therapeutics, where strategic direction for xRNA technologies and platforms is driven towards therapeutic applications. As Editor in Chief of Molecular Therapy Nucleic Acids and Scientific Advisor at Aptadel Therapeutics, Paloma Giangrande is involved in influential editorial and advisory roles within the field. Previously, as Vice President of Platform and Discovery Sciences at Wave Life Sciences, key responsibilities included overseeing RNA editing programs and managing cross-functional teams in drug development. Additional experience includes a Director role at Moderna Therapeutics and an academic career at the University of Iowa Hospitals and Clinics and Duke University Medical Center. Paloma Giangrande holds a PhD in Pharmacology and Cancer Biology from Duke University School of Medicine.